[CAS NO. 129298-91-5] TNP-470
PRODUCTS SPECIFICATIONS [129298-91-5]
DESCRIPTION [129298-91-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 401.88 |
| Molecular Formula | C19H28ClNO6 |
| SMILES | C[C@]1([C@@H](C/C=C(C)/C)O1)[C@]([C@@H]2OC)([H])[C@]3(CC[C@H]2OC(NC(CCl)=O)=O)CO3 |
Summary
TNP-470 is a methionine aminopeptidase-2 inhibitor and also an angiogenesis inhibitor.
In Vitro
No significant difference of apoptotic cell numbers is observed between cells treated with TNP-470 and the controls. The IC 50 s of TNP-470 are 16.86±0.9 µg/mL, 3.16±0.6 µg/mL and 1.78±0.8 µg/mL for KKU-M213 cells at 24, 48 and 72 h, respectively. The results show that TNP-470 significantly reduces the number of migrated cells and invaded cells as compare with the vehicle treated group. TNP-470 decreases the migrated cells of KKU-M213 to 26% and of KKU-M214 to 11% (P<0.01). Similarly, TNP-470 also significantly affects cell invasion, the number of invaded cells is reduced to 25% in KKU-M213 (P<0.01) and to 15% in KKU-M214 (P<0.01). The relative expressions of MMP2 , MMP9 and c-MYC in TNP-470 treated cells are significantly suppressed compare to the vehicle treated cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Treatment with TNP-470 attenuates (P<0.05) liver lipid accumulation compare to high fat fed (HFF) mice. By day 5, TNP-470 treated mice consume significantly less grams of high fat food than vehicle treated HFF mice. By day 15 of treatment, TNP-470 mice are consuming an equivalent number of calories to that of chow fed mice, despite the provision of high fat diet. Treatment with TNP-470 increases (P<0.05) expression of adipose tissue LPL mRNA, compare to chow-fed and high-fat fed controls. TNP-470 decreases energy intake and increases energy expenditure [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00000763 | National Institute of Allergy and Infectious Diseases (NIAID) |
Sarcoma, Kaposi|HIV Infections
|
Phase 1 | |
| NCT00038701 | M.D. Anderson Cancer Center |
Pancreatic Neoplasms
|
August 1999 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL ( 248.83 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4883 mL | 12.4415 mL | 24.8830 mL |
| 5 mM | 0.4977 mL | 2.4883 mL | 4.9766 mL |
| 10 mM | 0.2488 mL | 1.2442 mL | 2.4883 mL |
References
- [1] Kidoikhammouan S, et al. TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev. 2012;13 Suppl:155-60.
- [2] White HM, et al. The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice. Obesity (Silver Spring). 2012 Oct;20(10):2003-9.
Synonyms
